荷尔蒙避孕药市场－全球产业规模、份额、趋势、机会和预测（按方法、荷尔蒙、地区和竞争细分，2020-2030 年）

2024年，全球荷尔蒙避孕药市场规模达172.5亿美元，预计到2030年将达255.7亿美元，预测期内复合年增长率为6.78%。全球荷尔蒙避孕药市场正在经历显着增长，这得益于人们对口服避孕药使用及其在预防意外怀孕和控制人口方面的益处的认识不断提高，这显着增加了全球各地对荷尔蒙避孕药的需求。此外，随着荷尔蒙避孕药的使用率显着提高，以及不同年龄层女性对安全生活方式意识的不断增强，预计未来对不同荷尔蒙避孕方法的需求将进一步增加，从而推动市场成长。例如，2021 年 4 月，美国食品药物管理局批准了 Mayne Pharma 销售的屈螺酮和雌四醇复方片剂 Nextstellis，用于避孕，这是首批含有天然雌激素的复方药之一。

关键市场驱动因素

政府大力推行计划生育和生殖健康倡议

主要市场挑战

荷尔蒙避孕药的健康风险和副作用

主要市场趋势

长效可逆避孕药（LARC）日益受到青睐

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：临床试验分析

第六章：全球荷尔蒙避孕药市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依方法（避孕药、子宫内避孕器、注射、阴道环、植入物、其他）
  • 依激素（组合荷尔蒙避孕药和仅含黄体素的避孕药）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 依方法
  • 按激素
  • 按地区

第七章：北美荷尔蒙避孕药市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第八章：欧洲荷尔蒙避孕药市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第九章：亚太地区荷尔蒙避孕药市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第十章：南美洲荷尔蒙避孕药市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲荷尔蒙避孕药市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 驱动程式
• 挑战

第十三章：市场趋势与发展

• 最新动态
• 併购
• 产品发布

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品/服务的威胁

第 15 章：SWOT 分析：全球荷尔蒙避孕药市场

第 16 章：竞争格局

• Abbvie, Inc.
• Afaxys, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Merck KGaA
• Organon Group of Companies
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals, Inc.
• Pregna International Ltd.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Hormonal Contraceptives Market was valued at USD 17.25 Billion in 2024 and is expected to reach USD 25.57 Billion by 2030 with a CAGR of 6.78% during the forecast period. The global market for Hormonal Contraceptives is experiencing significant growth, driven by the growing awareness regarding usage of oral contraceptive and its benefits for preventing the unintended pregnancy and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, ahavetion of hormonal contraceptives has significantly increased and increasing awareness among women of different age group for leading the safe life is further expected to increase the demand for different hormonal contraceptives procedures, thereby fuelling the market growth. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen.

Key Market Drivers

Rising Government Initiatives to Promote Family Planning and Reproductive Health

One of the primary drivers of growth in the global hormonal contraceptives market is the significant investment by governments and international health organizations in reproductive health and family planning programs. Hormonal contraceptives-including oral pills, patches, injections, implants, and vaginal rings-form the cornerstone of modern contraception. Their widespread availability and integration into public health systems are largely supported by government policies that aim to reduce unintended pregnancies, maternal mortality, and child morbidity. The World Health Organization (WHO) states that around 257 million women globally who want to avoid pregnancy are not using safe or modern contraceptive methods. To address this unmet need, numerous governments have scaled up access to hormonal contraceptives through national programs. For instance, the U.S. federal Title X Family Planning Program supports clinics in offering affordable or free birth control to low-income individuals. According to the Office of Population Affairs (OPA), Title X clinics served 1.5 million individuals in 2022 alone, and over 99% of those clients received contraceptive services.

In developing countries, such as India, the Ministry of Health and Family Welfare operates the National Family Planning Program, which provides subsidized contraceptives through public health centers. As of 2023, the Indian government distributed over 20 million cycles of oral contraceptive pills under its Mission Parivar Vikas scheme. These expansive efforts ensure continuous market demand for hormonal contraceptives and stimulate innovation and supply chain efficiency. In effect, public health policies aimed at increasing contraceptive prevalence are driving hormonal contraceptive market growth across regions.

Key Market Challenges

Health Risks and Side Effects Associated with Hormonal Contraceptives

Despite their widespread use and effectiveness, hormonal contraceptives are associated with various health risks and side effects, which pose a significant challenge to market growth. Hormonal contraceptives function by altering a woman's hormone levels to prevent ovulation, and this hormonal interference can lead to adverse effects such as mood swings, weight gain, nausea, headaches, and menstrual irregularities. More serious risks include an increased likelihood of blood clots, cardiovascular complications, and, in rare cases, certain types of cancer. A study by the National Cancer Institute (NCI) reported a slight increase in the risk of breast and cervical cancer among long-term users of hormonal contraceptives, although they may reduce the risk of ovarian and endometrial cancers.

In 2019, the U.S. Food and Drug Administration (FDA) updated warnings on combined hormonal contraceptives (CHCs) about the risk of venous thromboembolism (VTE), especially for products containing drospirenone. Similarly, regulatory agencies in Europe, such as the European Medicines Agency (EMA), have recommended stronger warnings and educational efforts to ensure informed use. Concerns about side effects can lead to discontinuation or switching to non-hormonal methods, particularly in high-risk populations such as smokers over 35, obese individuals, and those with hypertension or a family history of thrombotic disorders. These health considerations reduce user confidence and affect market penetration, especially among new adopters. As awareness of potential adverse effects grows, particularly through social media and health advocacy platforms, it may hinder widespread adoption unless offset by education, personalized medical guidance, and the development of safer formulations.

Key Market Trends

Increasing Preference for Long-Acting Reversible Contraceptives (LARCs)

A prominent trend reshaping the hormonal contraceptives landscape is the growing preference for Long-Acting Reversible Contraceptives (LARCs) such as hormonal intrauterine devices (IUDs) and subdermal implants. These methods offer extended protection ranging from three to ten years, minimal maintenance, and high efficacy-qualities that are increasingly appealing to women globally, particularly those seeking convenience and long-term reproductive autonomy. According to the U.S. Centers for Disease Control and Prevention (CDC), LARCs have the lowest failure rates among contraceptive methods-less than 1%-compared to 7% for oral contraceptive pills. This reliability, combined with a low requirement for user adherence, has fueled rapid adoption, especially in developed countries with well-established healthcare systems.

Government programs are also promoting LARCs as part of comprehensive reproductive healthcare. For instance, the UK's National Health Service (NHS) includes hormonal IUDs in its publicly funded contraceptive offerings. In the U.S., state-level Medicaid expansion has been linked to increased access and uptake of LARCs, particularly in underserved populations. A report from the Kaiser Family Foundation found that the use of LARCs among U.S. women aged 15-44 increased from 8.5% in 2009 to 14% in 2020. In low- and middle-income countries, international bodies like UNFPA and USAID have rolled out LARC-focused initiatives to reduce unmet contraceptive needs. These global efforts, combined with innovations in hormonal implant technologies, are likely to sustain the rising demand for LARCs over the coming decade.

Key Market Players

• Abbvie, Inc.
• Afaxys, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Merck KGaA
• Organon Group of Companies
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals, Inc.
• Pregna International Ltd.

Report Scope:

In this report, the Global Hormonal Contraceptives Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hormonal Contraceptives Market, By Method:

• Pill
• Intrauterine Device
• Injectable
• Vaginal Ring
• Implant
• Others

Hormonal Contraceptives Market, By Hormone:

• Combination Hormonal Contraceptives
• Progestin Only

Hormonal Contraceptives Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hormonal Contraceptives Market.

Available Customizations:

Global Hormonal Contraceptives Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Hormonal Contraceptives Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)
  • 6.2.2. By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)
  • 6.2.3. By Region
  • 6.2.4. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Method
  • 6.3.2. By Hormone
  • 6.3.3. By Region

7. North America Hormonal Contraceptives Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Method
  • 7.2.2. By Hormone
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hormonal Contraceptives Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Method
      • 7.3.1.2.2. By Hormone
  • 7.3.2. Canada Hormonal Contraceptives Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Method
      • 7.3.2.2.2. By Hormone
  • 7.3.3. Mexico Hormonal Contraceptives Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Method
      • 7.3.3.2.2. By Hormone

8. Europe Hormonal Contraceptives Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Method
  • 8.2.2. By Hormone
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Hormonal Contraceptives Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Method
      • 8.3.1.2.2. By Hormone
  • 8.3.2. Germany Hormonal Contraceptives Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Method
      • 8.3.2.2.2. By Hormone
  • 8.3.3. United Kingdom Hormonal Contraceptives Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Method
      • 8.3.3.2.2. By Hormone
  • 8.3.4. Italy Hormonal Contraceptives Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Method
      • 8.3.4.2.2. By Hormone
  • 8.3.5. Spain Hormonal Contraceptives Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Method
      • 8.3.5.2.2. By Hormone

9. Asia-Pacific Hormonal Contraceptives Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Method
  • 9.2.2. By Hormone
  • 9.2.3. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Hormonal Contraceptives Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Method
      • 9.3.1.2.2. By Hormone
  • 9.3.2. India Hormonal Contraceptives Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Method
      • 9.3.2.2.2. By Hormone
  • 9.3.3. Japan Hormonal Contraceptives Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Method
      • 9.3.3.2.2. By Hormone
  • 9.3.4. South Korea Hormonal Contraceptives Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Method
      • 9.3.4.2.2. By Hormone
  • 9.3.5. Australia Hormonal Contraceptives Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Method
      • 9.3.5.2.2. By Hormone

10. South America Hormonal Contraceptives Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Method
  • 10.2.2. By Hormone
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hormonal Contraceptives Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Method
      • 10.3.1.2.2. By Hormone
  • 10.3.2. Argentina Hormonal Contraceptives Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Method
      • 10.3.2.2.2. By Hormone
  • 10.3.3. Colombia Hormonal Contraceptives Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Method
      • 10.3.3.2.2. By Hormone

11. Middle East and Africa Hormonal Contraceptives Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Method
  • 11.2.2. By Hormone
  • 11.2.3. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Hormonal Contraceptives Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Method
      • 11.3.1.2.2. By Hormone
  • 11.3.2. Saudi Arabia Hormonal Contraceptives Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Method
      • 11.3.2.2.2. By Hormone
  • 11.3.3. UAE Hormonal Contraceptives Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Method
      • 11.3.3.2.2. By Hormone

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Hormonal Contraceptives Market

16. Competitive Landscape

• 16.1. Abbvie, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Afaxys, Inc.
• 16.3. Teva Pharmaceuticals Industries Ltd.
• 16.4. Bayer AG
• 16.5. Merck KGaA
• 16.6. Organon Group of Companies
• 16.7. Pfizer Inc.
• 16.8. Johnson & Johnson Services, Inc.
• 16.9. Lupin Pharmaceuticals, Inc.
• 16.10. Pregna International Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer